1220696-34-3 Usage
Uses
Used in Pharmaceutical Industry:
1-Methyl-5-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[2,3-b]pyridine is used as a building block for the synthesis of pharmaceuticals due to its high stability and versatility in forming carbon-carbon and carbon-heteroatom bonds. Its unique structural features and functional groups enable the development of new chemical entities with potential biological activities, contributing to the discovery of novel drugs and therapeutic agents.
Used in Agrochemical Industry:
In the agrochemical industry, 1-Methyl-5-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[2,3-b]pyridine is used as a reagent in the synthesis of agrochemicals. Its ability to form carbon-carbon and carbon-heteroatom bonds makes it a valuable component in the development of new pesticides, herbicides, and other agrochemical products with improved efficacy and selectivity.
Used in Materials Science:
1-Methyl-5-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[2,3-b]pyridine is utilized in materials science as a key component in the synthesis of advanced materials with unique properties. Its versatility in forming various types of chemical bonds allows for the development of new materials with potential applications in areas such as electronics, energy storage, and nanotechnology.
Used in Organic Chemistry Research:
As a reagent in organic chemistry, 1-Methyl-5-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[2,3-b]pyridine is used for conducting research and exploring new reaction pathways. Its high stability and unique structural features make it an important tool for chemists to study and understand the mechanisms of various chemical reactions, leading to advancements in the field of organic chemistry.
Check Digit Verification of cas no
The CAS Registry Mumber 1220696-34-3 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,2,0,6,9 and 6 respectively; the second part has 2 digits, 3 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 1220696-34:
(9*1)+(8*2)+(7*2)+(6*0)+(5*6)+(4*9)+(3*6)+(2*3)+(1*4)=133
133 % 10 = 3
So 1220696-34-3 is a valid CAS Registry Number.
1220696-34-3Relevant academic research and scientific papers
2,4-DISUBSTITUTED PHENYLENE-1,5-DIAMINE DERIVATIVES AND APPLICATIONS THEREOF, AND PHARMACEUTICAL COMPOSITIONS AND PHARMACEUTICALLY ACCEPTABLE COMPOSITIONS PREPARED THEREFROM
-
, (2017/01/31)
The present invention provides a class of 2,4-substituted phenylene-1,5-diamine derivatives, having an inhibiting effect on EGFR tyrosine kinases, and pharmaceutically acceptable salt, stereoisomer, solvate or prodrug of said derivatives. See the description for the definition of each group in the formula. In addition, the present invention also discloses pharmaceutical compositions, pharmaceutically acceptable compositions and applications thereof.
DNA-PK INHIBITORS
-
Paragraph 0201; 0202; 0216, (2013/11/05)
The present invention relates to compounds useful as inhibitors of DNA-PK. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.
1H-IMIDAZO[4, 5-c]QUINOLINONE COMPOUNDS, USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES
-
Page/Page column 106, (2010/12/29)
The invention relates to the use of 1 H-imidazo[4,5-c]quinolinone compounds and salts thereof in the treatment of protein and/or lipid kinase dependent diseases and for the manufacture of pharmaceutical preparations for the treatment of said diseases; 1 H-imidazo[4,5-c]quinolinone compounds for use in the treatment of protein and/or lipid kinase dependent diseases; a method of treatment against said diseases, comprising administering the 1 H-imidazo[4,5-c]quinolinone compounds to a warm-blooded animal, especially a human; pharmaceutical preparations comprising an 1 H-imidazo[4,5-c]quinolinone compounds, especially for the treatment of a protein and/or lipid kinase dependent disease; novel 1 H-imidazo[4,5-c]quinolinone compounds; and a process for the preparation of the novel 1 H-imidazo[4,5-c]quinolinone compounds.
